Travere's commercial licence partner in Europe is non other than CSL who are busy commercialising sparsentan there for iga nephropathy. If/when Travere gets this over the line with FDA for FSGS, they'll surely submit for approval in Europe. Interesting market ahead.
DXB Price at posting:
48.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)